What To Expect From Danaher Corporation ($DHR) 3Q20 Earnings

Danaher Corporation (NYSE:DHR) is reporting third quarter earnings results on Thursday 22nd October 2020, before market open.

The consensus estimates from Thomson Reuters are income of $ 1.36 per share.

For the full year, analysts predict revenues of $ 21357.50 million, while looking forward to income of $ 5.51 per share.

The Company Outlook

Full Year 2020 bottomline are predicted in a range of $ 4.80 ~ $ 4.90 per share

Click Here For More Historical Outlooks Of Danaher Corporation

Previous Quarter Performance

Danaher Corporation unfold income for the second quarter of $ 1.44 per share, from the revenue of $ 5,297.00 million. The quarterly earnings 32.11 percent while revenues elevated 2.72 percent compared with the same quarter last year.
The consensus estimates are income of $ 1.08 per share from $ 4939.38 million in revenue. The bottom line results beat street analysts by $ 0.36 or 33.33 percent, at the same time, top line results outshined analysts by $ 357.62 million or 7.24 percent.

Stock Performance

Shares of Danaher Corporation traded up $ 1.09 or 0.48 percent on Wednesday, reaching $ 228.12 with volume of 1.74 million shares. The stock opened positive for the day at $ 228.76, after closing the previous day trading at $ 227.03.

According to the previous trading day, closing price of $ 227.03, representing a 89.82 % increase from the 52 week low of $ 119.60 and a 1.18 % decrease over the 52 week high of $ 229.75.

The company has a market capital of $ 161.83 billion and is part of the Healthcare sector and Diagnostics & Research industry.

Conference Call

Danaher Corporation will be hosting a conference call at 8:00 AM eastern time on 22nd October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The companys Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.

error: Content is protected !!
Exit mobile version